Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Sep;22(3):325–329. doi: 10.1111/j.1365-2125.1986.tb02894.x

The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non insulin dependent diabetics.

D R Owens, J Vora, T Morris, S Luzio, R E Ryder, J Atiea, T M Hayes
PMCID: PMC1401141  PMID: 3533123

Abstract

The metabolic effects of glucagon leading to hyperglycaemia are well recognised. However, the spasmolytic properties of glucagon have only relatively recently been utilised in clinical medicine. The marked hyperglycaemia accompanying the smooth muscle relaxant action of glucagon has led to the development of smaller peptides derived from glucagon which may retain the spasmolytic effects without the metabolic consequences. This study compares the metabolic and hormonal response to one such peptide, glucagon-(1-21)-peptide, with the parent peptide glucagon. The results demonstrate that glucagon-(1-21)-peptide has no metabolic effects comparable to glucagon. In normal subjects and non-insulin dependent diabetics, glucagon-(1-21)-peptide has no stimulatory effect on the pancreatic beta-cell.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Frandsen E. K., Grønvald F. C., Heding L. G., Johansen N. L., Lundt B. F., Moody A. J., Markussen J., Vølund A. Glucagon: structure-function relationships investigated by sequence deletions. Hoppe Seylers Z Physiol Chem. 1981 Jun;362(6):665–677. doi: 10.1515/bchm2.1981.362.1.665. [DOI] [PubMed] [Google Scholar]
  2. Heding L. G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia. 1972 Aug;8(4):260–266. doi: 10.1007/BF01225569. [DOI] [PubMed] [Google Scholar]
  3. Heding L. G. Radioimmunological determination of human C-peptide in serum. Diabetologia. 1975 Dec;11(6):541–548. doi: 10.1007/BF01222104. [DOI] [PubMed] [Google Scholar]
  4. STAUB A., SINN L., BEHRENS O. K. Purification and crystallization of hyperglycemic glycogenolytic factor (HGF). Science. 1953 Jun 5;117(3049):628–629. doi: 10.1126/science.117.3049.628. [DOI] [PubMed] [Google Scholar]
  5. Stower M. J., Foster G. E., Hardcastle J. D. A trial of glucagon in the treatment of painful biliary tract disease. Br J Surg. 1982 Oct;69(10):591–592. doi: 10.1002/bjs.1800691011. [DOI] [PubMed] [Google Scholar]
  6. Wünsch E. Die Totalsynthese des Pankreas-Hormons Glucagon. Z Naturforsch B. 1967 Dec;22(12):1269–1276. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES